Welcome to SynAging SAS

Your R&D partner for in vitro and in vivo phenotypic models in wild type, accelerating drug discovery for sporadic neurodegenerative diseases.

News

SynAging has new phone and fax numbers in 2017! The old numbers will stop working soon!

SynAging will be present at the following meetings in 2017:

 BioFIT 2017, November 28-29, Strassbourg, France, meet us at booth C4

SynAging' past meetings in 2017:

Neuroscience R&D Technologies Conference, September 28-29, London, UK - Presentation on Sept. 29

Genesis Drug Discovery, October 11-12, Frankfurt Main, Germany - Presentation on Oct. 11

BIO-Europe 2017, November 6-8, Berlin, Germany

European Brain & Behavior Society Meeting, September 8-11, Bilbao, Spain

20 Years of alpha-synuclein in Parkinsion's disease and related synucleopathies Meeting in Athens, September 7-10, 2017

EuroTau Meeting, April 27-28, Lille, France

International Conference on Alzheimer's & Parkinson’s Diseases 2017 - Booth 14a, at the entrance of the exhibition & Posters
March 29 . – April 2., Vienna, Austria

SynAging's past meetings:

Press & Publications

SynAging's Poster won the 'Best Poster Award' here during the '20 Years of alpha-synuclein in Parkinsion's disease and related synucleopathies' meeting in Athens, September 7-10, 2017 entitled:
PATHOLOGICAL ALPHA-SYNUCLEIN PREPARATIONS INDUCE COGNITIVE IMPAIRMENT AND NEURODEGENERATION
Download PDF
 

Poster EBBS Meeting 2017: PRION-LIKE SOLUBLE MISFOLDED PROTEIN OLIGOMERS INDUCE NEURODEGENERATION: RELEVANCE FOR PARKINSON’S AND ALZHEIMER’S DISEASE MODELS
Download PDF

Dietary arachidonic acid increases deleterious effects of amyloid-β oligomers on learning abilities and expression of AMPA receptors: putative role of the ACSL4-cPLA2 balance;  Link

Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy
Link

ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer’s Disease
Link

HUMAN TAU OLIGOMERS INDUCE NEURODEGENERATION: TAUOPATHY MODELS FOR TARGET VALIDATION AND DRUG DEVELOPMENT
Download PDF

HUMAN ALPHA-SYNUCLEIN OLIGOMERS BUT NOT 'SPREADING' FIBRILS INDUCE EARLY COGNITIVE DECLINE IN MICE
Download PDF

SynAging's human tau oligomer poster at SFN 2016
Download PDF

SynAging's alpha synuclein oligomer poster at SFN 2016
Download PDF

SynAging's Alzheimers disease poster at AAIC 2016
Download PDF

SynAging's Parkinson's disease poster at AAIC 2016
Download PDF

 

In vitro Human Models of Neurodegeneration in Parkinson´s Disease

Human iPSC-derived (HIP™) neurons from Thermo Fisher (before MTI-GlobalStem) are seeded, differentiated for five weeks and matured in 96 well plates for five weeks. The cultures contain 60% neurons and 40% astroglial cells.

The expression of the following markers has been verified by Western blot analysis: β-tubulin, SNAP25, GFAP, and total tau (see below).The neurons have been verified to express PSD95 and synaptophysine in a DAPI stained background of nuclei by immunohistochemistry (see: human AD in vitro model).

The presence of dopaminergic neurons in the human neuronal culture has been verified by Western blot for dopamine transporter (DAT), tyrosine hydroxylase (TH), and α-synuclein:

The 5 weeks matured human neuronal cultures are treated for 72 h with SynAging’s human α-synuclein oligomer (aSO) preparation (1 µM, based on monomer), with or without BDNF. The readout indicating neuronal survival in this mixed culture of neurons and astroglia is a specific marker for neurons: ELISA for neuron specific enolase (NSE, see reference below).

(Ref.: Oliva D, Calì L, Feo S, Giallongo A (1991). "Complete structure of the human gene encoding neuron-specific enolase.". Genomics 10 (1): 157–65)

Further read-outs are available for this model:

  • Gene and protein expression changes by RT-qPCR, immunoblot, or ELISA
  • Protein phosphorylation
  • Validated ELISA quantification of synaptic markers from neurons: e.g. PSD95, Synaptophysin, SNAP25
  • Oxidative Stress

SynAging’s in vitro human PD assay can investigate three test items, or three test item concentrations, per plate in triplicate with the following groups:

  • Vehicle (vehicle control)
  • aSO (negative control)
  • aSO + BDNF (positive control)
  • Test Item + vehicle
  • Test Item + aSO

 

Please contact us to discuss your interests and requirements for this model.

Product Sheet In vitro PD Screen on Human Neurons” Download PDF, 550 KB